2-deoxy-2-fluoro-D-[UL-13C6]glucose

2-deoxy-2-fluoro-D-[UL-13C6]glucose is a radiolabeled form of 2-deoxy-2-fluoro-D-glucose (FDG), which is a commonly used radiopharmaceutical for medical imaging. It is used in positron emission tomography (PET) scans to identify and locate cancerous tissues, as well as to detect various neurological and cardiovascular disorders. The radiolabeled version of FDG, 2-deoxy-2-fluoro-D-[UL-13C6]glucose, is used in research studies to trace glucose metabolism in cells and tissues. Chemically, 2-deoxy-2-fluoro-D-[UL-13C6]glucose is a modified form of glucose, where the hydroxyl group at the 2-position is replaced with a fluorine atom. The radiolabeled carbon atoms in the molecule allow for tracking of its uptake and metabolism in cells using imaging techniques. The compound is typically administered intravenously, and is rapidly taken up by cells that have high glucose metabolism, such as cancer cells. While 2-deoxy-2-fluoro-D-[UL-13C6]glucose is generally considered safe for use in medical imaging and research studies, it is important to note that it is a radioactive compound, and precautions should be taken to minimize exposure to radiation. Additionally, patients with diabetes or other metabolic disorders may require special considerations when undergoing imaging with FDG or its derivatives. Overall, 2-deoxy-2-fluoro-D-[UL-13C6]glucose is a valuable tool for medical imaging and research, allowing for non-invasive tracking of glucose metabolism in cells and tissues.